OBJECTIVE To assess whether routine postpartum human papillomavirus (HPV) vaccination is acceptable and feasible and to identify key themes and strategies that can be used to increase postpartum HPV vaccination rates. DATA SOURCES PubMed and ClinicalTrials.gov were queried from inception to July 2024 for postpartum and HPV vaccination. Studies were limited to human subjects and the English language. METHODS OF STUDY SELECTION Screening was performed for studies of any method that evaluated HPV vaccination in the postpartum period (N=60). Only original research that reported either uptake or acceptability of the HPV vaccine was included. Thirty-nine studies were eliminated after abstract review because they did not meet the inclusion criteria. TABULATION, INTEGRATION, AND RESULTS Nine studies were categorized according to the primary aim of the study (defining the problem, assessing patient perspectives, or testing interventions to increase vaccination) and demonstrated that postpartum HPV vaccination programs can significantly increase HPV vaccination rates and are feasible and acceptable to patients. CONCLUSION Incorporating HPV vaccination into standard postpartum care provides an opportunity to reach vulnerable patient populations, reduces cost for patients, and has the ability to prevent HPV-related cancers.

中文翻译：

---

产后人乳头瘤病毒疫苗接种：系统评价。


目的 评估常规产后人乳头瘤病毒 (HPV) 疫苗接种是否可接受和可行，并确定可用于提高产后 HPV 疫苗接种率的关键主题和策略。数据来源 PubMed 和 ClinicalTrials.gov 从成立到 2024 年 7 月对产后疫苗接种和 HPV 疫苗接种进行了查询。研究仅限于人类受试者和英语。研究选择方法 对任何评估产后 HPV 疫苗接种的方法的研究进行筛选 (N=60)。仅包括报告 HPV 疫苗的吸收或可接受性的原始研究。摘要审查后，有 39 项研究因不符合纳入标准而被淘汰。制表、整合和结果 九项研究根据研究的主要目的（定义问题、评估患者观点或测试增加疫苗接种的干预措施）进行分类，并证明产后 HPV 疫苗接种计划可以显着提高 HPV 疫苗接种率并且是可行的并为患者所接受。结论 将 HPV 疫苗接种纳入标准产后护理为接触弱势患者群体提供了机会，降低了患者的成本，并且能够预防 HPV 相关癌症。